A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0143-0406 A 0.6 mmol/L in Subjects With Type 1 Diabetes
Phase of Trial: Phase I
Latest Information Update: 14 Aug 2017
At a glance
- Drugs NN 1406 (Primary) ; Insulin aspart
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 29 Jun 2016 Status changed from active, no longer recruiting to completed.
- 30 May 2016 Status changed from recruiting to active, no longer recruiting.
- 01 Dec 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.